Among Anthropic's partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. In addition, the company has launched its own programs for the search and development of new drugs.
At Generate Biomedicences, researchers used Claude Code to rewrite the genetic instructions for CAR-T cell therapy, which is primarily used to treat blood cancers. According to Anthropic, the Claude variant was 70% shorter than the standard version and showed better results in laboratory tests. Currently, the team is working on adapting the method to combat solid tumors.
At Divergence Labs, Claude developed approximately 35,000 antibody variants for the treatment of food allergies in a month. Scientists selected three variants capable of binding to immunoglobulin E (a molecule involved in allergic reactions), and another 20 variants capable of separating this molecule from immune cells. According to Anthropic, three of them performed better than the standard pharmaceutical product in tests.
At BigHat Biosciences, researchers also used Claude for work on antibodies. The most effective variants demonstrated better binding to the target and increased stability compared to the original molecules.
In addition to scientific research, laboratories have turned to Claude for process optimization. So, Enveda sent pharmaceutical production documentation to a system based on Claude. The AI found all 11 errors that previous human specialists had identified, and seven additional ones, while reducing the inspection time by 89%. At Bristol Myers Squibb, they want to use Claude to analyze and improve the development plans of promising drugs and assess the probability of trial success.
In addition, Anthropic announced the acquisition of Mithril Medicine, a company developing a drug for two rare forms of muscular dystrophy. Founder of Mithril Medicine Cody Tranbarger used Claude to coordinate experiments in 11 external laboratories and manage other research processes. Anthropic reported that within less than 18 months of research, tests on mice showed promising results. The company expects to transition to human clinical trials of the drug by the end of 2028.
